A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
暂无分享，去创建一个
M. Robson | S. Domchek | S. Attwell | K. Punie | Karen Norek | J. Litton | V. Boni | P. Sharma | E. Campeau | Mafalda Oliveira | E. Hamilton | A. Gucalp | P. Aftimos | P. Shah | M. D. de Miguel | M. Silverman | L. Bauman | Sanjay Lakhotia | Margo Snyder | Emily Johnson